Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) EBITDA Margin (2019 - 2025)

Silo Pharma (SILO) has disclosed EBITDA Margin for 7 consecutive years, with 4920.93% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 477616.0% to 4920.93% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5858.77% through Dec 2025, up 22183.0% year-over-year, with the annual reading at 5858.77% for FY2025, 22183.0% up from the prior year.
  • EBITDA Margin hit 4920.93% in Q4 2025 for Silo Pharma, up from 6150.66% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 574643.9% in Q4 2021 to a low of 9697.09% in Q4 2024.
  • Historically, EBITDA Margin has averaged 29040.05% across 5 years, with a median of 5043.41% in 2023.
  • Biggest five-year swings in EBITDA Margin: soared 57025009bps in 2021 and later tumbled -58386853bps in 2022.
  • Year by year, EBITDA Margin stood at 574643.9% in 2021, then tumbled by -102bps to 9224.63% in 2022, then skyrocketed by 32bps to 6250.31% in 2023, then tumbled by -55bps to 9697.09% in 2024, then soared by 49bps to 4920.93% in 2025.
  • Business Quant data shows EBITDA Margin for SILO at 4920.93% in Q4 2025, 6150.66% in Q3 2025, and 6687.56% in Q2 2025.